Table 2.

The effects of paracetamol on BP: randomised controlled trials

Study	Design	Patient	n	Age (years)	Paracetamol dose	Duration	Baseline systolic BP (mmHg)	End systolic BP (mmHg)	Change in systolic BP (mmHg)
Chalmers et al. 40	Randomized, double-blind, two phase, crossover, placebo- controlled	HTN OA	22	–	1 g three times daily	4 weeks	–	–	4
Lewis et al. 41	Unblinded, three phase, crossover	HTN OA	21	62	1 g four times daily	2 weeks	110.3 (MAP)	103.8 (MAP)	−6.5 (MAP)
Radack et al. 42	Randomized, double-blind, parallel groups, placebo controlled	HTN	15	53	1 g four times daily	3 weeks	123	–	0.2
Chau et al. 43	Randomized, double-blind, three phase, crossover	HTN	12	31–71	650 mg	Once	–	121 ± 12	1.2 ± 6.0
Pavlicevic et al. 44	Randomized, single-blind, three phase, parallel groups	HTN	49	70	1 g three times daily	1 month	139.3L	133.9L/I/Pa	−5.4
							133.3L	132.9L/P/Pa	−0.4
							144.8A	142.0A/I/Pa	−2.8
							130.2A	131.4A/P/Pa	1.2
Sudano et al. 28	Randomized, double-blind, two phase, crossover, placebo controlled	CAD	33	61	1 g three times daily	2 weeks	122	125	3

A, amlodipine; CAD, coronary artery disease; HTN, hypertension; I, ibuprofen; L, lisinopril/hydrochlorothiazide; MAP, mean arterial pressure; OA, osteoarthritis; P, piroxicam; Pa, paracetamol.